Vigil Neuroscience to Present at Jefferies Inaugural Biotech CNS/Neuro Summit
October 05 2023 - 3:01PM
Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage
biotechnology company committed to harnessing the power of
microglia for the treatment of neurodegenerative diseases, today
announced that Ivana Magovčević-Liebisch, Ph.D., J.D., President
and Chief Executive Officer, and David Gray, Ph.D., Chief Science
Officer, will participate in a fireside chat at the Jefferies
Inaugural Biotech CNS/Neuro Summit on Thursday, October 12, 2023,
at 1:30 p.m. ET.
To access the live event, please click here to
register for the webcast. The webcast will also be available on the
Company’s website under the “Events & Presentations” page in
the “Investors” section. An archived webcast will be available for
approximately 90 days following the presentation.
About Vigil NeuroscienceVigil
Neuroscience is a clinical-stage biotechnology company focused on
developing treatments for both rare and common neurodegenerative
diseases by restoring the vigilance of microglia, the sentinel
immune cells of the brain. We are utilizing the tools of modern
neuroscience drug development across multiple therapeutic
modalities in our efforts to develop precision-based therapies to
improve the lives of patients and their families. VGL101, our lead
clinical candidate, is a fully human monoclonal antibody agonist
targeting human triggering receptor expressed on myeloid cells 2
(TREM2) in people with adult-onset leukoencephalopathy with axonal
spheroids and pigmented glia (ALSP), a rare and fatal
neurodegenerative disease. We are also developing VG-3927, a novel
small molecule TREM2 agonist, to treat common neurodegenerative
diseases associated with microglial dysfunction, with an initial
focus on Alzheimer’s disease (AD) in genetically defined
subpopulations.
Internet Posting of
InformationVigil Neuroscience routinely posts information
that may be important to investors in the “Investors” section of
its website at https://www.vigilneuro.com. The company encourages
investors and potential investors to consult our website regularly
for important information about Vigil Neuroscience.
Investor Contact:Leah Gibson Vice President,
Investor Relations & Corporate CommunicationsVigil
Neuroscience, Inc.lgibson@vigilneuro.com
Media Contact:Megan McGrathMacDougall
Advisorsmmcgrath@macdougall.bio
Vigil Neuroscience (NASDAQ:VIGL)
Historical Stock Chart
From May 2024 to Jun 2024
Vigil Neuroscience (NASDAQ:VIGL)
Historical Stock Chart
From Jun 2023 to Jun 2024